Petra Selchow

Petra Selchow

Auto-generated profile, based on publicly available information

Petra Selchow

Institute of Medical Microbiology, University of Zurich

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2021 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
DSDaniel Schäfle
Daniel Schäfle
PSPetra Selchow
Petra Selchow
BBBarbara Borer
Barbara Borer
MMMichael Meuli
Michael Meuli
ARAnna Rominski
Anna Rominski
PSPeter Sander
Peter Sander
Mycobacterium abscessus exhibits arr (ADP-ribosyltransferase)-dependent rifampin resistance. In apparent contrast, rifabutin (RBT) has demonstrated promising activity in M. abscessus infection models, implying that RBT might not be inactivated by Arr.

2 January 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
GPGregory A. Phelps
Gregory A. Phelps
MCMartin N. Cheramie
Martin N. Cheramie
DFDinesh M. Fernando
Dinesh M. Fernando
PSPetra Selchow
Petra Selchow
CMChristopher J. Meyer
Christopher J. Meyer
RLRichard E. Lee
Richard E. Lee
Mycobacterium abscessus(Mab), a nontuberculous mycobacterial (NTM) species, is an emerging pathogen with high intrinsic drug resistance. Current standard-of-care therapy results in poor outcomes, demonstrating the urgent need to develop effective antimycobacterial regimens. Through synthetic modification of spectinomycin (SPC), we have identified a distinct structural subclass of N-ethylene linked aminomethyl SPCs (eAmSPCs) that are up to 64-fold more potent againstMabover the parent SPC. Mechanism of action and crystallography studies demonstrate that the eAmSPCs display a mode of ribosomal inhibition consistent with SPC. However, they exert their increased antimicrobial activity through enhanced accumulation, largely by circumventing efflux mechanisms. The N-ethylene linkage within this series plays a critical role in avoiding TetV-mediated efflux, as lead eAmSPC 2593 displays a mere fourfold susceptibility improvement againstMabΔtetV,in contrast to the 64-fold increase for SPC. Even a minor shortening of the linkage by a single carbon, akin to 1st generation AmSPC 1950, results in a substantial increase in MICs and a 16-fold rise in susceptibility againstMabΔtetV. These shifts suggest that longer linkages might modify the kinetics of drug expulsion by TetV, ultimately shifting the equilibrium towards heightened intracellular concentrations and enhanced antimicrobial efficacy. Furthermore, lead eAmSPCs were also shown to synergize with various classes of anti-Mabantibiotics and retain activity against clinical isolates and other mycobacterial strains. Encouraging pharmacokinetic profiles coupled with robust efficacy inMabmurine infection models suggest that eAmSPCs hold the potential to be developed into treatments forMaband other NTM infections.

16 July 2026 in Applied and Environmental Microbiology
Verified
Journal Article
Open access
TGTizian Griesser
Tizian Griesser
PSPetra Selchow
Petra Selchow
PSPeter Sander
Peter Sander
Mycobacterium abscessus is a clinically important multidrug-resistant pathogen for which genetic manipulation remains challenging. Here, we developed a second-generation genetic toolbox based on leucine auxotrophy that enables antibiotic-free positive selection. A Δ leuB mutant, lacking the gene encoding isopropyl malate dehydrogenase in the leucine biosynthesis pathway, was generated by targeted gene deletion. This mutant requires exogenous leucine for growth and can be complemented by plasmid-borne leuB , establishing a robust auxotrophy-based selection system. To support genetic manipulation, we constructed a suite of second-generation vectors, including a multicopy replicative vector (pRep-amp- leuB ), a single-copy integrative vector (pInt-amp- leuB ), and a suicide vector (pSuc-amp- leuB ) for allelic replacement. These vectors enable gene overexpression, complementation, and targeted gene deletion, respectively, without reliance on aminoglycoside resistance markers. Using this system, we demonstrate efficient transformation and functional complementation of the Δ leuB mutant, achieving high transformation efficiencies and near-zero background growth under leucine selection. In contrast to antibiotic-based systems, this approach eliminates nonspecific background and avoids activation of stress response pathways, such as the whiB7 regulon. Overall, this auxotrophy-based toolbox provides a versatile platform for precise genetic manipulation in M. abscessus , improving selection stringency and enabling antibiotic-free functional genomics approaches, as demonstrated by deleting aac(2 ′), eis2, and a 19-kb fragment of the gpl locus. IMPORTANCE: The development of a leucine auxotroph-based genetic system for Mycobacterium abscessus addresses critical challenges in mycobacterial genetics. By avoiding established antibiotic resistance markers, this approach reduces selective pressure for antibiotic-resistant transformants, supports antibiotic stewardship, and minimizes costly disposal from laboratory waste. It also avoids unintended activation of whiB7 , a master regulator of approximately 100 genes, particularly those involved in antibiotic stress responses, thereby improving the accuracy of phenotypic drug susceptibility testing. The versatile genetic toolbox developed here, including novel replicative, integrative, and suicide plasmids, provides precise control over functional studies, overexpression, complementation, and gene deletion. It significantly reduces dependency on antibiotics for genetic manipulation, aligning with the goals of sustainable research and offering new opportunities for studying this clinically significant pathogen. This approach represents a critical advance in microbial genetics, enhancing our capacity to explore the molecular basis of pathogenesis and drug resistance in M. abscessus .